Iron Deficiency and Hereditary Haemorrhagic Telangiectasia

Hereditary Haemorrhagic Telangiectasia Clinical Trial

Official title:

Iron Deficiency and Hereditary Haemorrhagic Telangiectasia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01908543
• Other study ID #: CLS 2013/1
• Status: Terminated
• Phase: N/A
• Start date: July 2013
• Est. completion date: July 2015

Study information

• Verified date: September 2023
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Managing iron deficiency is important for more than 1 billion individuals worldwide, to avoid blood transfusions, or excessive strain on vital organs that depend on iron-containing haemoglobin to deliver oxygen to the tissues. Iron deficiency is a particular problem for people with the inherited condition hereditary haemorrhagic telangiectasia (HHT). Their iron deficiency and anaemia results from blood losses, especially from the nose (nosebleeds, and they often need additional iron to replace that lost through bleeding.

Our goal is to stratify HHT patients into high/low absorbers of iron; to define what extra iron they need to adjust for their current and likely future blood losses; and to work out how to achieve this most safely for each individual to improve their later health.

We will test the hypothesis that informed assessment of iron intake and post absorption cellular profiles changes the recommendations for iron intake for HHT patients.

Description:

Relevant patients due to come to clinic or the programmed investigation unit will be offered the opportunity to participate in the study.

Up to 100 consenting individuals will

• have an additional 15 mls of supplementary research bloods taken

• receive a single tablet of ferrous sulphate 200mg

• fill in questionnaires that formally evaluate their nosebleed losses and dietary iron intake in the preceding 12 months

• have a second blood sample later that day (20 mls of blood)

The primary outcome measure is the change in serum iron levels post iron tablet.

Other outcome measures will include:

• Haematinic indices indicating whether their iron requirements have been met previously.

• Additional predicted iron intake requirements to adjust for haemorrhagic iron losses

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Hereditary haemorrhagic telangiectasia (HHT). Definite diagnosis of HHT by international criteria.

• No iron tablets or treatment taken on day of assessment

• Ability to provide informed consent.

Exclusion Criteria:

• Inability to provide informed consent

• Intercurrent infection or illness predicted to modify iron absorption.

• Needle phobia.

Related Conditions & MeSH terms

• Anemia, Iron-Deficiency
• Hereditary Haemorrhagic Telangiectasia
• Telangiectasia, Hereditary Hemorrhagic
• Telangiectasis

Intervention

Drug:
• Ferrous sulphate 200mg oral tablet
Administration by mouth

Locations

Country	Name	City	State
United Kingdom	Wellcome Trust-McMichael Clinical Research Facility, Imperial college London London, United Kingdom W12 0NN	London

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood iron indices		4-5 hours after iron tablet ingestion